Seattle Genetics, Inc., a biotechnology company, engages in the development of monoclonal antibody-based therapies for the treatment of cancer and immunologic diseases. Its products are based on two technologies, genetically engineered monoclonal antibodies and monoclonal antibody-drug conjugates, which develop monoclonal antibodies that kill target cells and raise the potency of monoclonal antibodies by linking them to a cell killing payload. The company’s product candidates include SGN-30, a monoclonal antibody targeting the CD30 antigen, which is in phase II clinical trials for treatment of systemic anaplastic large cell lymphoma (ALCL), cutaneous ALCL, and...
To see the headquarters in Google Street View &trade, drag this yellow guy: 
over to the red pointer: 
